Related Experiment Video

Updated: Sep 8, 2025

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.7K

Taxane-induced neuropathy: How serious is this problem for patients with early breast cancer?

Robert Nicolae1, Anthony Uccellini1, Jim Siderov1

  • 1Austin Health, Olivia Newton-John Cancer Wellness and Research Centre Melbourne, Melbourne, Australia.

Asia-Pacific Journal of Clinical Oncology
|June 13, 2022
PubMed
Abstract

Insights

Taxane-induced peripheral neuropathy (TIPN) is common in breast cancer patients receiving paclitaxel, often leading to reduced treatment intensity. Some patients experience persistent TIPN one year after treatment completion.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Taxanes are essential in breast cancer treatment.
  • Taxane-induced peripheral neuropathy (TIPN) is a frequent and debilitating side effect.
  • Current literature lacks consistent data on TIPN's frequency, severity, risk factors, and management.

Purpose of the Study:

  • To analyze the frequency, severity, and impact of TIPN in early-stage breast cancer patients treated with weekly paclitaxel.
  • To identify clinicopathological and patient-related risk factors for TIPN.

Main Methods:

  • Retrospective chart review of 348 early-stage breast cancer patients treated with weekly paclitaxel (2010-2020).
  • Analysis of TIPN occurrence, severity, and treatment impact during therapy and at one-year follow-up.
  • Collection of clinicopathological and patient data to identify risk factors.

Main Results:

  • 80.2% of patients developed TIPN during treatment.
  • TIPN was associated with significantly lower dose intensity (p < 0.001).
  • Neoadjuvant treatment and body surface area were independent risk factors for TIPN during treatment. Increased age and pre-treatment diabetes were associated with persistent TIPN at one year.

Conclusions:

  • TIPN is highly prevalent in breast cancer patients receiving weekly paclitaxel.
  • TIPN necessitates dose reductions and treatment cessation, impacting overall dose intensity.
  • Prospective studies are needed to further investigate long-term outcomes of TIPN.
Keywords:
TIPN: taxane-induced peripheral neuropathyearly breast cancer treatment

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.3K
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

23.2K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
259
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
366
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
438